Symbiotec Pharmalab shares may list at 19% premium
In short
Symbiotec Pharmalab shares are due to start trading today. The grey market premium is said to be ₹185, which points to an estimated listing price of about ₹1,173 per share, above the IPO price of ₹988.
This matters because it hints at investor demand for the stock. The real opening price is still unknown from the available reporting.
What the reporting says
Symbiotec Pharmalab shares are set to list today, with grey market trends pointing to about a 19% premium over the IPO price. The publisher-supplied summary says the grey market premium is ₹185, implying an estimated listing price of around ₹1,173 versus the issue price of ₹988. The actual listing outcome is not stated in the available reporting.
Why it matters
Symbiotec Pharmalab shares are scheduled to list today, and the publisher-supplied summary says grey market trading points to a 19% premium over the ₹988 IPO price. That implies an estimated listing around ₹1,173 per share. The reporting does not confirm the actual debut price, investor response, or whether the GMP holds at listing.